Editors Note: Data presentations to be showcased at the 54th ERA-EDTA Congress
NxStage Medical, Inc. (Nasdaq: NXTM), today announced new findings demonstrating positive biochemical outcomes related to more frequent hemodialysis with the NxStage® System One™. The data will be presented at the ERA-EDTA Congress being held June 3-6, 2017, in Madrid, Spain.
The research was conducted by the Knowledge to Improve Home Dialysis Network in Europe (KIHDNEy) Cohort team with two poster presentations by lead authors Drs. Maxence Ficheux, Nephrologist, CHR Clémenceau, Caen, France and Roberto Corciulo Nephrologist, Azienda Ospedaliero-Universitaria Policlinico, Bari, Italy, as well as, symposium presentations by Dr. Sunita Nair, Consultant Nephrologist and Clinical Lead, Home Dialysis Therapy Shrewsbury and Telford NHS Trust, UK, outlining the KIHDNEy Cohort, 12-month results, and Pr. Eric Goffin Nephrologist and Clinical Lead, Cliniques Universitaires Saint Luc, Brussels, Belgium, focusing on mineral and bone disorders. Conference attendees can meet with NxStage representatives in booth 3.155.
PRESENTATIONS: Oral presentations will occur on Sunday, June 4th at 6:45 p.m. CEST during the symposium, More Frequent HD Improved Outcomes: The Wish Comes True At Home, chaired by Drs. Natalie Borman, Medical Director, Consultant Nephrologist, Wessex Renal and Transplantation Unit, Portsmouth, UK, and Maria-Auxiliadora-Bajo, Nephrologist, Hospital Universitario La Paz, Madrid, Spain. Also during the symposium, Matthew Herbert, a NxStage patient from the United Kingdom, will discuss his dialysis journey and experiences on home nocturnal hemodialysis with the NxStage System One.
Of the 11 KIHDNEy researchers 3 of the contributors will be in attendance to present data, from the 182 patients across 9 renal units in 5 countries, highlighting the clinical benefits of more frequent home hemodialysis, including:
- Improved control of fluid volume and good clearance of solutes:
- Low ultrafiltration rate,
- Reduction in antihypertensive medications,
- Adequate dose of dialysis.
- Stable mineral and bone disease parameters, along with improved albumin
- Good preservation of residual renal function
Allan Collins, Chief Medical Officer, NxStage Medical, “Data continues to reaffirm that more frequent hemodialysis with the System One provides better health outcomes for a broad spectrum of dialysis patients. He added, We are excited to be sharing this data with the international renal care community and look forward to working together to provide greater patient access to this life-changing therapy option.”
The NxStage System One is a simple, flexible and portable hemodialysis system that provides a wide range of dialysis therapy options, including home, more frequent, and nocturnal dialysis. Visit nxstage.com for more information on therapy options with the System One.
Company notes: Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.